Vesalio Announces Initial Use of its Uniquely Designed and FDA-approved NeVa VS Device
Vesalio Introduces pVasc™ U.S. Clinical Study to capture real-world data and optimize results for patients suffering from peripheral vascular disease.
Vesalio appoints VP of U.S. Sales and announces recent publication on NeVa showing impressive first pass rates
Vesalio hires Bob Bushok as VP of U.S. Sales and announces high first-pass rates and favorable safety profile in a 145-stroke patient data set for the NeVa™ thrombectomy device with findings published in the journal Interventional Neuroradiology.
Vesalio announces EU MDR Certification
MDR certification confirms the company’s commitment of ensuring that their innovative new products meet or exceed these rigorous new standards.
Vesalio announces FDA Approval of the NeVa VS™
NeVa VS is a patented retrievable nitinol stent specifically designed to treat cerebral vasospasm after aneurysmal rupture.
Vesalio announces CE Approval for new NeVa NET™
The first integrated clot micro-filtration technology for stroke thrombectomy patients.
Vesalio announces oversubscribed Class A financing
Vesalio, an emerging leader in improving outcomes in patients with vascular occlusion, is proud to announce it has oversubscribed its Class A financing round.
Vesalio Announces Completion of Enrollment in its FDA Enabling Stroke Study
Vesalio announces the completion of enrollment in its FDA IDE clinical study for acute ischemic stroke.
Vesalio Announces Earl Slee as New Board Observer and Senior Advisor to the Company
As a board observer and senior advisor to the company, Earl Slee brings extensive medical device innovation and business development expertise.
Vesalio Announces Appointment of Mike Kujak as its New Independent Board Chairman
As an independent board chairman, Mike Kujak will bring expert knowledge and know-how from his years of leadership in the medical device start-up space.
Vesalio Initiates Clinical Study Evaluating Innovative Thrombectomy Technique for Patients with STEMI
Vesalio announced the start of enrollment in its NATURE study using enVast™, the company’s first thrombectomy system for patients presenting with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.
